Lenacapavir by Gilead demonstrates 96% reduction in HIV infections in clinical trial.
A recent study has shown that Gilead’s new HIV prevention injectable drug, lenacapavir, has proven to reduce HIV infections by 96%. This positive phase-three trial data indicates the potential approval of lenacapavir by the U.S. Food and Drug Administration for HIV prevention. Pre-exposure prophylaxis (PrEP) medication is taken to prevent acquiring HIV. Gilead’s twice-yearly shot was found to be 89% more effective than the daily pill, Truvada, in preventing HIV. The drug was well-tolerated by patients with no new safety concerns reported. Jefferies analyst Michael Yee stated that the data on lenacapavir is consistent and solid across different study populations. The results of the trial are expected to lead to FDA approval and market launch by 2025.
SOURCE
Emily Jensen, graduated from the London School of Economics and Political Science (LSE) in the UK in 2015 with a degree in Economics. She specializes in financial markets and international trade. After graduating, she worked as an analyst at an investment bank in London, where she developed expertise in global economic trends. She later transitioned into consulting, focusing on fintech ventures and providing insights into global economic developments. Emily is passionate about the intersection of finance and technology and aims to drive innovation in the financial sector.